<DOC>
	<DOCNO>NCT00250705</DOCNO>
	<brief_summary>The propose study 6-week open label study evaluate aripiprazole treatment 12 male post-pubertal adolescent ( 13-17 year , Tanner Stage 4 ) diagnose conduct disorder . The initial dose depend weight patient follow : &lt; 25 kg = 1 mg/d ; 25-50 kg = 2 mg/d ; 50-70 kg = 5 mg/d ; &gt; 70 kg = 10 mg/d ( Data File , 2003 , Bristol-Myers Squibb ) . For first two week study , dose flexible base response tolerance thereafter remain fixed .</brief_summary>
	<brief_title>Trial Aripiprazole Treatment CD Adolescents</brief_title>
	<detailed_description>The use atypical antipsychotic child begin 1992 several small case series clozapine . Since time , five atypical agent , risperidone , olanzapine , quetiapine , ziprasidone aripiprazole introduce US market . The new atypical agent associate agranulocytosis limited usefulness clozapine . Among atypical antipsychotic , risperidone remain extensively studied child adolescent , variety problem , include Tourette 's disorder , conduct disorder , schizophrenia , aggression , pervasive development disorder . Risperidone show effective treatment many disorder . However , weight gain , hyperprolactinemia , extrapyramidal symptom ( EPS ) troublesome adverse effect commonly associate risperidone drug 's utility age patient population limit . We expect utility aripiprazole treat pediatric population limit adverse effect like atypical antipsychotic .</detailed_description>
	<mesh_term>Conduct Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Male postpubertal adolescent ( 1317 year , Tanner Stage 4 ) diagnose conduct disorder . Clinically significant laboratory and/or ECG abnormalities Preexisting health condition would compromise patient safety Mental retardation Previous use aripiprazole Active psychosis</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Aripiprazole</keyword>
</DOC>